PIPELINE

Scaling new heights in early disease interception

Pipeline MiRXES 2021

Addressing clinical unmet needs across the entire continuum of care

Cancer Early Interception Pipeline

Cancer Early Detection

RNA-powered multi-cancer multi-omics screening tests.

+ Gastric cancer screening test is first to be launched.
+ Lung cancer screening test to be launched by end 2021.
+ Tests for colorectal, liver, breast, pancreatic, and ovarian cancer to follow.

Precision Oncology

Fast turn-around testing services for cancer treatment guidance and resistance prediction.

+ Launching APEX tissue and liquid biopsy testing services with 4-day turn-around.
+ Testing for comprehensive genomic profiling, immunotherapy, haematology-oncology, and somatic mutations to follow.

Disease Early Detection Pipeline

Non-oncology Diagnostics

Multi-omics early detection and companion diagnostic tests for infectious, cardiovascular, and metabolic diseases.
+ Gastric cancer screening test is first to be launched.
+ Lung cancer screening test to be launched by end 2021.
+ Tests for colorectal, liver, breast, pancreatic, and ovarian cancer to follow.

Cancer Early Interception Pipeline

Cancer Early Detection

RNA-powered multi-cancer multi-omics screening tests.

+ Gastric cancer screening test is first to be launched.
+ Lung cancer screening test to be launched by end 2021.
+ Tests for colorectal, liver, breast, pancreatic, and ovarian cancer to follow.

Precision Oncology

Fast turn-around testing services for cancer treatment guidance and resistance prediction.

+ Launching APEX tissue and liquid biopsy testing services with 4-day turn-around.
+ Testing for comprehensive genomic profiling, immunotherapy, haematology-oncology, and somatic mutations to follow.

Disease Early Detection Pipeline

Non-oncology Diagnostics

Multi-omics early detection and companion diagnostic tests for infectious, cardiovascular, and metabolic diseases.
+ Gastric cancer screening test is first to be launched.
+ Lung cancer screening test to be launched by end 2021.
+ Tests for colorectal, liver, breast, pancreatic, and ovarian cancer to follow.

The continuum of care:

Read more about our latest and key scientific publications here.

24 Mar 2021

Mammography is extensively used for breast cancer screening but has high false-positive rates. This paper describes the discovery, development, and validation of a serum 6-miRNA panel to discriminate between malignant and benign breast lesions among women with abnormal mammograms. 

24 Feb 2021

Cross-platform evaluation study led by Merck (MSD) scientists showing that MiRXES ID3EAL miRNA qPCR platform has superior reproducibility and detection rate compared to other commercial miRNA profiling platforms (Exiqon qPCR, Qiagen qPCR, Applied Biosystems qPCR, NanoString nCounter, and miRNA-Seq) when used for discovery and validation of blood-based miRNA biomarkers.

24 Feb 2021

Cross-platform evaluation study led by Merck (MSD) scientists showing that MiRXES ID3EAL miRNA qPCR platform has superior reproducibility and detection rate compared to other commercial miRNA profiling platforms (Exiqon qPCR, Qiagen qPCR, Applied Biosystems qPCR, NanoString nCounter, and miRNA-Seq) when used for discovery and validation of blood-based miRNA biomarkers.

24 Feb 2021

Cross-platform evaluation study led by Merck (MSD) scientists showing that MiRXES ID3EAL miRNA qPCR platform has superior reproducibility and detection rate compared to other commercial miRNA profiling platforms (Exiqon qPCR, Qiagen qPCR, Applied Biosystems qPCR, NanoString nCounter, and miRNA-Seq) when used for discovery and validation of blood-based miRNA biomarkers.

24 Feb 2021

Cross-platform evaluation study led by Merck (MSD) scientists showing that MiRXES ID3EAL miRNA qPCR platform has superior reproducibility and detection rate compared to other commercial miRNA profiling platforms (Exiqon qPCR, Qiagen qPCR, Applied Biosystems qPCR, NanoString nCounter, and miRNA-Seq) when used for discovery and validation of blood-based miRNA biomarkers.

24 Feb 2021

Cross-platform evaluation study led by Merck (MSD) scientists showing that MiRXES ID3EAL miRNA qPCR platform has superior reproducibility and detection rate compared to other commercial miRNA profiling platforms (Exiqon qPCR, Qiagen qPCR, Applied Biosystems qPCR, NanoString nCounter, and miRNA-Seq) when used for discovery and validation of blood-based miRNA biomarkers.

Copyright © 2021 MiRXES Pte Ltd. All rights reserved. | Privacy Policy
Scroll to Top